INmune Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

INmune Bio hat ein Gesamteigenkapital von $38.7M und eine Gesamtverschuldung von $2.5M, was einen Verschuldungsgrad von 6.4% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $52.8M bzw. $14.1M.

Wichtige Informationen

6.4%

Verhältnis von Schulden zu Eigenkapital

US$2.49m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$33.55m
Eigenkapital	US$38.68m
Gesamtverbindlichkeiten	US$14.11m
Gesamtvermögen	US$52.78m

Jüngste Berichte zur Finanzlage

Recent updates

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Nov 03

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 30

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

Jul 12

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

Jan 19

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Sep 04

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

May 12

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

Jan 16

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

Jul 11

INmune Bio: Possibly The Once In A Lifetime Dip

May 25

INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors

Apr 05

Is INmune Bio (NASDAQ:INMB) A Risky Investment?

Mar 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: INMBDie kurzfristigen Aktiva des Unternehmens ($35.9M) übersteigen seine kurzfristigen Passiva ($13.8M).

Langfristige Verbindlichkeiten: INMBDie kurzfristigen Vermögenswerte des Unternehmens ($35.9M) übersteigen seine langfristigen Verbindlichkeiten ($284.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: INMB über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: INMBDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 6.4% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: INMB auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: INMB hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 25.7% pro Jahr abnimmt

INmune Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

Recent updates

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

New major risk - Revenue and earnings growth

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

INmune Bio, Inc. to Report Q3, 2024 Results on Oct 31, 2024

CFO, Treasurer & Secretary recently bought US$53k worth of stock

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Co-Founder recently bought US$98k worth of stock

INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio, Inc. has filed a Follow-on Equity Offering.

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus EPS estimates upgraded to US$2.26 loss

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™? on Proteins That Regulation Synapse in Alzheimer's Patients

INmune Bio, Inc. to Report Q2, 2024 Results on Aug 01, 2024

It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial

INmune Bio, Inc., Annual General Meeting, Jul 19, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022)

Consensus EPS estimates fall by 24%

INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial

INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million.

Independent Director recently bought US$246k worth of stock

Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024

INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro

Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program

New minor risk - Share price stability

Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?

INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA

Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe

Consensus revenue estimates increase by 30%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line

INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference

INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?

Consensus revenue estimates increase by 51%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy

Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer

Insufficient new directors

INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

Price target decreased to US$14.33

Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease

Consensus revenue estimates increase by 24%

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021)

INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune